[Featured Stock] PhiloSys Rises on Subsidiary's Technology Acquisition Amid COVID-19 'Plasma Therapy' Push

[Asia Economy Reporter Minwoo Lee] As the government promotes 'plasma therapy' for the treatment of the novel coronavirus infection (COVID-19), the stock price of Philosis Healthcare, an affiliate of Philosis with related technology, is on the rise.

As of 2:20 PM on the 1st, Philosis Healthcare is showing 1,510 KRW, up 11.9% from the previous day. After the quarantine authorities established a policy to use convalescent plasma from recovered patients for the treatment of severe COVID-19 cases, Philosis Healthcare has attracted attention due to its affiliate Philosis, which possesses blood glucose measurement technology necessary for plasma therapy.

Plasma therapy utilizes the fact that antibodies are formed in the plasma of people who have recovered from a specific disease, transfusing the plasma of recovered patients to other patients to build resistance. This treatment was also used during the 2015 Middle East Respiratory Syndrome (MERS) outbreak.